TABLE 4.
Cumulative amenorrhea rates with menopausal hormone therapiesa
| Products | Doses | Cumulative amenorrhea (%) cycle 1 to cycle 13 |
| Oral | ||
| Prempro (CEE/MPA; Wyeth Pharmaceuticals Inc, Philadelphia, PA)17 | 0.625 mg/5 mg | 26 |
| 0.625 mg/2.5 mg | 23 | |
| 0.45 mg/1.5 mg | 42 | |
| 0.3 mg/1.5 mg | 45 | |
| Activella (E2/NETA; Novo Nordisk Inc, Princeton, NJ)18 | 1 mg/0.5 mg | 49 |
| Angeliq (E2/DRSP; Bayer Healthcare, Whippany, NJ)19 | 1 mg/0.5 mg | 45 |
| TX-001HR (E2/P4) | 1 mg/100 mg | 56 |
| 0.5 mg/100 mg | 68 | |
| 0.5 mg/50 mg | 69 | |
| 0.25 mg/50 mg | 73 | |
| Placebo (REPLENISH trial) | 81 | |
| Transdermal patch | ||
| CombiPatch (E2/NETA; Novartis Pharmaceuticals, East Hanover, NJ)20 | 0.05 mg/0.14 mg0.05 mg/0.25 mg | 279 |
| Climara Pro (E2/LNG; Berlex, Montville, NJ)21 | 0.045 mg/ 0.015 mg | 16 |
CEE, conjugated equine estrogens; DRSP, drospirenone; E2, 17β-estradiol; EE, ethinyl estradiol; LNG, levonorgestrel; MPA, medroxyprogesterone acetate; NETA, norethisterone acetate; P4, progesterone.
aBased on prescribing information or clinical data; not a head-to-head comparison.